The International Society for Biological Therapy of Cancer (iSBTc) 25th Annual Meeting: Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc Biomarker Task ForceSeptember 30, 2010Building 10, Clinical CenterNational Institutes of Health CampusBethesda, MDProgram OrganizersLisa H. Butterfield, PhD - University of PittsburghMary L. (Nora) Disis, MD - University of WashingtonSamir N. Khleif, MD - National Cancer Institute (CCR)Francesco Marincola, MD - National Institutes of Health (CC, DTM)Program SummaryThis symposium aims achieve several goals. One is to define minimum quality standards and procedures for laboratories developing immunologic biomarkers for clinical trial analyses. The second is to discuss development of potency assays and the reporting of immunologic results. Third, review the current data supporting correlations of immunity and clinical outcome, and how knowledge from other fields (other then immunotherapy of cancer) can contribute to cancer immunotherapy. Lastly, determine which novel and high through-put technologies are now appropriate for use in cancer immunotherapy trials. Target AudienceThe target audience for these programs incorporates basic and clinical investigators from academic, regulatory and biopharmaceutical venues. The audience includes clinicians, researchers, students, post-doctoral fellows and allied health professionals.
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us